Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of phosphoinositol 3-kinase, was granted accelerated approval by the United States Food and Drug Administration on the basis of its activity in the third-line treatment of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Lymphoma Myeloma Leuk
Main Authors: Cheson, Bruce D., O’Brien, Susan, Ewer, Michael S., Goncalves, Marcus D., Farooki, Azeez, Lenz, Georg, Yu, Anthony, Fisher, Richard I., Zinzani, Pierre L., Dreyling, Martin
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6642803/
https://ncbi.nlm.nih.gov/pubmed/30584024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.11.021
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker